BioSpace News Archive

Avicanna (AVCNF) today announced that Aras Azadian, CEO, will be attending the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 24th @ 2:00PM ET

The International Myeloma Foundation launched a multiyear, multidisciplinary initiative called “M-Power Charlotte,” designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the African-American community.

Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease, announced today that the company has initiated a Phase 2 study evaluating the efficacy of RBT-1 on acute kidney injury (AKI) prevention in subjects undergoing coronary artery bypass

Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, reported financial results for the fourth quarter and full year ended December 31, 2020 and reviewed business highlights.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced it will participate in the 33rd Annual ROTH Conference,

Abbott (NYSE: ABT) today announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific and public health partnership dedicated to the early detection of, and rapid response to, future pandemic threats

Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations

Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today the acquisition of Swift Biosciences, a pioneer in the development of Next-Generation Sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research. IDT is a leader in developing and manufacturing nucleic acid products for academic and commercial research,

EMulate Therapeutics Inc, a clinical-stage therapeutic device company, announced that management will participate in the Venture Summit...